-
公开(公告)号：KR1020000019717A
公开(公告)日：2000-04-15
申请号：KR1019980037959
申请日：1998-09-15
Applicant: 한국과학기술연구원
IPC: A61K31/70
CPC classification number: A23L2/52 , A21D2/14 , A23C9/13 , A23C9/152 , A23L7/109 , A23L13/428 , A23L23/00 , A23L27/63 , A61K31/70 , Y10S514/824 , A61K2300/00
Abstract: PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoids are provided, for treating and preventing hyper lipidemia, arteriosclerosis and a liver disease. CONSTITUTION: The pharmaceutical composition comprises rutin, quercetin or their mixture ineffective amount; and pharmaceutically acceptable carriers. The functional food comprises 0.01-10 wt% of rutin, quercetin or their mixture. Rutin can be obtained from a fruit, a leaf, a trunk and a flower of buck wheat and be used in the form of a powder or an extract. Rutin and quercetin being bioflavonoids inhibit HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester in the body. Therefore rutin and quercetin reduce the concentration of cholesterol in blood, inhibit strongly a macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and protect a liver.
Abstract translation: 目的：提供包含生物类黄酮的药物组合物和功能性食品，用于治疗和预防高脂血症，动脉硬化和肝脏疾病。 构成：药物组合物含有芦丁，槲皮素或其混合物无效量; 和药学上可接受的载体。 功能性食品包含0.01-10重量％的芦丁，槲皮素或其混合物。 芦丁可以从水果，叶子，树干和小麦花中获得，并以粉末或提取物的形式使用。 芦丁和槲皮素是生物类黄酮抑制作为还原酶的HMG CoA（3-羟基-3-甲基戊二酰辅酶），其涉及胆固醇和ACAT（酰基CoA;胆固醇-O-酰基转移酶）的生物合成，其将胆固醇转化为身体中的胆固醇酯 。 因此，芦丁和槲皮素降低血液中胆固醇的浓度，强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面，并保护肝脏。
-
-
-
公开(公告)号：KR100291144B1
公开(公告)日：2001-05-15
申请号：KR1020000058789
申请日：2000-10-06
Applicant: 한국과학기술연구원
IPC: A61K31/70
Abstract: 본 발명은 디오스민(diosmin)을 포함하는 동맥경화증 및 고지혈증의 예방 및 치료용 조성물에 관한 것으로, 디오스민은 동물에게 투여되었을 때 동맥내피에 대식세포-지질 복합체가 침착되는 것을 강력히 억제할 뿐만 아니라, ACAT 및 HMG-CoA 환원효소의 활성을 억제하고, 혈중 콜레스테롤 및 중성지질의 농도를 감소시키므로, 동맥경화증 및 고지혈증의 예방 및 치료제로서 유용하게 사용될 수 있다.
-
15.发明公开탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는동맥경화증, 고지혈증 및 지방간의 예방 및 치료용 식품조성물 无效食品复合材料用于预防和治疗阿片样物质，高胆固醇和包括鞣制或鞣制酚醛化合物的肝硬化
公开(公告)号：KR1020010030556A
公开(公告)日：2001-04-16
申请号：KR1020000062335
申请日：2000-10-23
Applicant: 한국과학기술연구원
Abstract: PURPOSE: Food composites including tannin or tannin-derived phenolics are provided to prevent and treat arteriosclerosis, hyperlipidemia and hepatic steatosis by dosing tannin, gallic acid or/and ellagic acid. CONSTITUTION: Tannin, gallic acid or/and ellagic acid is/are added to a food or a drink to prevent and treat arteriosclerosis. Tannin(C76H52O46) is extracted from acorns, persimmons and walnut shells. Gallic acid(C7H6O5) and ellagic acid(C14H6O8) are the decomposition products of tannin and have anticancer activities. The amount of the tannin-derived phenolics is from 0.01wt.% to 20wt.% according to the weight, age, gender, health status, diet, dosage time and method, excretory rate and disease level of patients.
Abstract translation: 目的：提供包括单宁或单宁衍生物酚类的食品复合材料，以预防和治疗单宁，没食子酸或鞣花酸的动脉硬化，高脂血症和肝脂肪变性。 构成：将单宁，没食子酸或/和鞣花酸加入到食物或饮料中以预防和治疗动脉硬化。 单宁（C76H52O46）从橡子，柿子和核桃壳中提取。 没食子酸（C7H6O5）和鞣花酸（C14H6O8）是单宁的分解产物，具有抗癌活性。 根据体重，年龄，性别，健康状况，饮食，剂量时间和方法，患者的排泄率和病情水平，单宁衍生物酚类的含量为0.01重量％〜20重量％。
-
Patent Agency Ranking
公开(公告)号：KR1020010015510A
公开(公告)日：2001-02-26
申请号：KR1020000062334
申请日：2000-10-23
Applicant: 한국과학기술연구원
IPC: A61K31/366
Abstract: PURPOSE: A composition containing tannin, gallic acid or ellagic acid is provided for preventing and treating arteriosclerosis, hyperlipemia and liver diseases. CONSTITUTION: When tannin, gallic acid or ellagic acid are administrated into an animal body, they prevent the deposition of macrophage-lipid complex within the inner surface of arterial duct, decrease the concentration of GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase), gammaGTP(gamma-glutamyl transpeptidase), and lipid in serum, and strongly inhibit the damage of liver cells and the progress of fatty liver. The composition contains an effective of ellagic acid displaying an anticancer activity, that is 0.1 mg to 500 mg/weight kg a day. The composition is preferably administrated into an animal body 5 times a day in a dosage of 1 mg to 100 mg/weight kg.
Abstract translation: 目的：提供含有单宁，没食子酸或鞣花酸的组合物，用于预防和治疗动脉硬化，高脂血症和肝脏疾病。 构成：当将单宁，没食子酸或鞣花酸施用于动物体内时，可防止巨噬细胞 - 脂质复合物在动脉管内表面沉积，降低GOT（谷氨酸 - 草酰乙酸转氨酶）浓度，GPT（谷氨酸 - 丙酮酸转氨酶），γGTP（γ-谷氨酰转肽酶）和血清中的脂质，并且强烈地抑制肝细胞的损伤和脂肪肝的进展。 组合物含有显示抗癌活性的有效的鞣花酸，即每天0.1mg至500mg /重量kg。 组合物优选以1mg至100mg / kg kg的剂量每天施用5次。
-
公开(公告)号：KR1020010015495A
公开(公告)日：2001-02-26
申请号：KR1020000058705
申请日：2000-10-06
Applicant: 한국과학기술연구원
IPC: A23L1/29
Abstract: PURPOSE: A pharmaceutical composition containing one of rutin and Quercetin or the mixture is provided to prevent and treat hyperlipidemia, arteriosclerosis and liver diseases. CONSTITUTION: The rutin is extracted from buckwheat or leaves, stems and flowers of the buckwheat by leaving the materials at a base of pH10-12 by using calcium hydroxide, neutralizing and settling the materials, or by using 20-97% alcohol or water at a high temperature and pressure. The buckwheat and the leaves, stems and flowers also can be dried and pulverized to get powdered buckwheat. The resulting buckwheat flour or buckwheat extract containing 0.01-10wt% of the rutin, quercetin or the mixture of them is added to tomato ketchup, sauce and juice, ramen, noodle, bread, cookies and cracker, soup and gravies, ground beef, or dairy products to get functional foods.
Abstract translation: 目的：提供含有芦丁和槲皮素之一或混合物的药物组合物，用于预防和治疗高脂血症，动脉硬化和肝脏疾病。 构成：通过使用氢氧化钙将材料置于pH10-12的碱性条件下，从荞麦或荞麦的荞麦或叶子，茎和花中提取芦丁，中和和沉淀材料，或通过使用20-97％的酒精或水 高温高压。 荞麦和叶子，茎和花也可以干燥和粉碎以得到荞麦粉。 将含有0.01-10重量％的芦丁，槲皮素或其混合物的荞麦面粉或荞麦提取物加入番茄酱，酱汁和果汁，拉面，面条，面包，饼干和饼干，汤和肉汁，碎牛肉或 乳制品获得功能性食品。
-
公开(公告)号：KR1019950009904A
公开(公告)日：1995-04-26
申请号：KR1019930017870
申请日：1993-09-07
Applicant: 한국과학기술연구원
IPC: H01L21/20
Abstract: 본 발명에 기판상에 비정질 규소 박막을 증착시킨 후, 이를 특정 압력 하에 저온에서 열처리하여 고상 결정화시키는 것으로 이루어진 입자 크기가 큰 다결정 규소 박막을 제조하는 방법이 기재되어 있다. 본 발명의 방법은 결정 성장 온도를 크게 낮춤으로써 값비싼 석영 대신 값싼 유리 등의 기판을 사용하고, 고가의 Si
2 H
6 가스 대신 SiH
4 가스를 사용함으로써 다결정 규소 박막의 생산 단가를 크게 낮출 수 있을 뿐 만 아니라, 입자 크기가 150μ이상인 다결정 규소 박막을 제공함으로써 다결정 규소 박막의 전자 및 정공의 이동도를 단결정 수준으로 향상시켜 현재 어려움을 겪고 있는 LCD용 TFT나 SRAM용 TFT등의 고성능 SOI소자 개발을 획기적으로 진전시킬 수 있다.-
19.发明公开네오헤스페리딘 디하이드로칼콘을 포함하는 동맥경화증,고지혈증, 간 질환, 고혈당증의 예방 및 치료용 조성물 失效含有NEOHESPERIDIN DIHYDROCHALCONE的组合物可用于预防和治疗ARTERIOSCLEROSIS，HYPERLIPEMIA，肝脏疾病和GLYCOSEMIA
公开(公告)号：KR1020010007624A
公开(公告)日：2001-01-26
申请号：KR1020000058788
申请日：2000-10-06
Applicant: 한국과학기술연구원
IPC: A61K31/70
Abstract: PURPOSE: A composition containing neohesperidin dihydrochalcone generally used as a sweetener is provided for preventing and treating arteriosclerosis, hyperlipemia, liver diseases, and glycosemia. CONSTITUTION: Neohesperidin dihydrochalcone(C28H36O15, M.W. 612.60) is obtained by extracting from the rind or outer layer of grapefruit or by chemically changing Naringin, and it is sweeter 1,500 to 2,000 times than sugar per unit weight. Therefore it has been usually used as a sweetener not a medicinal material. The composition containing an effective amount of neohesperidin dihydrochalcone, that is, 0.1 to 500 mg/kg, preferably 1 to 100 mg/kg a day, is orally or topically administrated into a patient and the amount of administration may be variable by patient's age, weight, sex, health, diet, severity of disease, and so on. The composition containing neohesperidin dihydrochalcone may be added into foods and drinks in an amount of 0.01 to 20 wt.%, preferably 0.1 to 5 wt.% of diosmin.
Abstract translation: 目的：提供通常用作甜味剂的含有新皮质激素二氢查耳酮的组合物，用于预防和治疗动脉硬化，高脂血症，肝脏疾病和糖血症。 构成：通过从葡萄柚的外层或外层提取或通过化学改变柚皮苷获得新的皮肤色素二氢查耳酮（C28H36O15，M.W.612.60），并且比单位重量的糖更甜1,500-2000倍。 因此，它通常用作不是药用材料的甜味剂。 将包含有效量的新橙皮苷二氢查耳酮，即0.1至500mg / kg，优选1至100mg / kg每天的组合物口服或局部施用于患者，并且施用量可以由患者的年龄， 体重，性别，健康，饮食，疾病严重程度等。 含有新橙皮苷二氢查耳酮的组合物可以以diosmin的0.01〜20重量％，优选0.1〜5重量％的量添加到食品和饮料中。
-
20.发明公开탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물 无效包含从鞣剂衍生的鞣制或酚醛化合物的组合物，用于预防和治疗高脂血症，肠梗塞和肝病
公开(公告)号：KR1020000019718A
公开(公告)日：2000-04-15
申请号：KR1019980037961
申请日：1998-09-15
Applicant: 한국과학기술연구원
IPC: A61K31/045
CPC classification number: A23G3/368 , A21D2/14 , A21D2/145 , A21D2/181 , A21D2/36 , A23C9/152 , A23F3/14 , A23L2/56 , A23L33/105 , A61K31/70 , Y10S514/824 , A61K31/35 , A61K31/19 , A61K2300/00
Abstract: PURPOSE: A pharmaceutical composition and functional food and drink comprising tannin or phenol-type compounds derived from tannin are provided, for treating and preventing hyper lipidemia, arteriosclerosis and a liver disease. CONSTITUTION: The pharmaceutical composition comprises tannin, gallic acid, ellagic acid or their mixture in effective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of tannin, gallic acid, ellagic acid or their mixture. Tannin, gallic acid and ellagic acid reduce the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase), gamma GTP (gamma-glutamyl transpeptidase) and a lipid in blood, and inhibit the damage of a liver cell and the formation of a fatty liver. Also tannin, gallic acid and ellagic acid strongly inhibit the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface.
Abstract translation: 目的：提供包含单宁衍生的单宁或酚型化合物的药物组合物和功能性食品和饮料，用于治疗和预防高脂血症，动脉硬化和肝脏疾病。 构成：药物组合物含有有效量的单宁，没食子酸，鞣花酸或其混合物; 和药学上可接受的载体。 功能性食品或饮料包含0.01-20重量％，优选0.1-5重量％的单宁，没食子酸，鞣花酸或其混合物。 单宁，没食子酸和鞣花酸降低血清GOT（谷氨酸 - 草酰乙酸转氨酶），GPT（谷氨酸 - 丙酮酸转氨酶），γGTP（γ-谷氨酰转肽酶）和血脂中的血清浓度，抑制肝细胞损伤 并形成脂肪肝。 单宁，没食子酸和鞣花酸强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面。
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.02 seconds)
